May 16, 2026
AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial
AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.
1 source
00